Table 1.
Patients’ features.
| Patients | Feature | N (%) | |
|---|---|---|---|
| Gender, n(%) | Male | 21 (53.8) | |
| Female | 18 (46.2) | ||
| Age, median | 60.7 [25–80 y] | ||
| Primary origin | Midgut | 7 (17.9) | |
| Pancreatic | 19 (48.7) | ||
| Cerebral | 1 (2.6) | ||
| Bronchial | 6 (15.4) | ||
| CUP | 5 (12.8) | ||
| Pheocromocytoma | 1 (2.6) | ||
| Grading (%) | Median 8% [1–40%] |
G1 | 4 (19.3) |
| G2 | 31 (77.4) | ||
| G3 | 3 (3.3) | ||
| NET Syndrome | Functioning | 9 (23.1) | |
| Nonfunctioning | 30 (76.9) | ||
| PRRT Scheme | MONO | 23 (59) | |
| DUO | 16 (41) | ||
Abbreviations: CUP = NET of unknown primary origin; N = number; NET = neuroendocrine tumors; PRRT = peptide receptor radionuclide therapy.